Cargando…

Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging

BACKGROUND: Kidney Disease Improving Global Outcomes (KDIGO) 2013 updated the classification and risk stratification of chronic kidney disease (CKD) to include both the level of renal function and urinary albumin excretion (UAE). The update subclassifies the previous category of moderate renal impai...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Robert A, Wang, Yiting, Zhu, Vivienne, Rupnow, Marcia FT
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091951/
https://www.ncbi.nlm.nih.gov/pubmed/24990184
http://dx.doi.org/10.1186/1756-0500-7-415
_version_ 1782480817129259008
author Bailey, Robert A
Wang, Yiting
Zhu, Vivienne
Rupnow, Marcia FT
author_facet Bailey, Robert A
Wang, Yiting
Zhu, Vivienne
Rupnow, Marcia FT
author_sort Bailey, Robert A
collection PubMed
description BACKGROUND: Kidney Disease Improving Global Outcomes (KDIGO) 2013 updated the classification and risk stratification of chronic kidney disease (CKD) to include both the level of renal function and urinary albumin excretion (UAE). The update subclassifies the previous category of moderate renal impairment. There is currently limited information on the prevalence of CKD based on this new classification in United States (US) adults with type 2 diabetes mellitus (T2DM). The objective of this study was to provide such estimates, for T2DM both overall and in those ≥ 65 years of age. We used the continuous National Health and Nutrition Examination Survey (NHANES) 1999–2012 to identify participants with T2DM. Estimated glomerular filtration rate (eGFR) and UAE were calculated using laboratory results and data collected from the surveys, and categorized based on the KDIGO classification. Projections for the US T2DM population were based on NHANES sampling weights. RESULTS: A total of 2915 adults diagnosed with T2DM were identified from NHANES, with 1466 being age ≥ 65 years. Prevalence of CKD based on either eGFR or UAE was 43.5% in the T2DM population overall, and 61.0% in those age ≥ 65 years. The prevalence of mildly decreased renal function or worse (eGFR < 60/ml/min/1.73 m(2)) was 22.0% overall and 43.1% in those age ≥ 65 years. Prevalence of more severe renal impairment (eGFR < 45 ml/min/1.73 m(2)) was 9.0% overall and 18.6% in those age ≥ 65 years. The prevalence of elevated UAE (> 30 mg/g) was 32.2% overall and 39.1% in those age ≥ 65 years. The most common comorbidities were hypertension, retinopathy, coronary heart disease, myocardial infarction, and congestive heart failure. CONCLUSIONS: This study confirms the high prevalence of CKD in T2DM, impacting 43.5% of this population. Additionally, this study is among the first to report US prevalence estimates of CKD based on the new KDIGO CKD staging system.
format Online
Article
Text
id pubmed-4091951
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40919512014-07-11 Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging Bailey, Robert A Wang, Yiting Zhu, Vivienne Rupnow, Marcia FT BMC Res Notes Research Article BACKGROUND: Kidney Disease Improving Global Outcomes (KDIGO) 2013 updated the classification and risk stratification of chronic kidney disease (CKD) to include both the level of renal function and urinary albumin excretion (UAE). The update subclassifies the previous category of moderate renal impairment. There is currently limited information on the prevalence of CKD based on this new classification in United States (US) adults with type 2 diabetes mellitus (T2DM). The objective of this study was to provide such estimates, for T2DM both overall and in those ≥ 65 years of age. We used the continuous National Health and Nutrition Examination Survey (NHANES) 1999–2012 to identify participants with T2DM. Estimated glomerular filtration rate (eGFR) and UAE were calculated using laboratory results and data collected from the surveys, and categorized based on the KDIGO classification. Projections for the US T2DM population were based on NHANES sampling weights. RESULTS: A total of 2915 adults diagnosed with T2DM were identified from NHANES, with 1466 being age ≥ 65 years. Prevalence of CKD based on either eGFR or UAE was 43.5% in the T2DM population overall, and 61.0% in those age ≥ 65 years. The prevalence of mildly decreased renal function or worse (eGFR < 60/ml/min/1.73 m(2)) was 22.0% overall and 43.1% in those age ≥ 65 years. Prevalence of more severe renal impairment (eGFR < 45 ml/min/1.73 m(2)) was 9.0% overall and 18.6% in those age ≥ 65 years. The prevalence of elevated UAE (> 30 mg/g) was 32.2% overall and 39.1% in those age ≥ 65 years. The most common comorbidities were hypertension, retinopathy, coronary heart disease, myocardial infarction, and congestive heart failure. CONCLUSIONS: This study confirms the high prevalence of CKD in T2DM, impacting 43.5% of this population. Additionally, this study is among the first to report US prevalence estimates of CKD based on the new KDIGO CKD staging system. BioMed Central 2014-07-02 /pmc/articles/PMC4091951/ /pubmed/24990184 http://dx.doi.org/10.1186/1756-0500-7-415 Text en Copyright © 2014 Bailey et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bailey, Robert A
Wang, Yiting
Zhu, Vivienne
Rupnow, Marcia FT
Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
title Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
title_full Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
title_fullStr Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
title_full_unstemmed Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
title_short Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging
title_sort chronic kidney disease in us adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving global outcomes (kdigo) staging
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091951/
https://www.ncbi.nlm.nih.gov/pubmed/24990184
http://dx.doi.org/10.1186/1756-0500-7-415
work_keys_str_mv AT baileyroberta chronickidneydiseaseinusadultswithtype2diabetesanupdatednationalestimateofprevalencebasedonkidneydiseaseimprovingglobaloutcomeskdigostaging
AT wangyiting chronickidneydiseaseinusadultswithtype2diabetesanupdatednationalestimateofprevalencebasedonkidneydiseaseimprovingglobaloutcomeskdigostaging
AT zhuvivienne chronickidneydiseaseinusadultswithtype2diabetesanupdatednationalestimateofprevalencebasedonkidneydiseaseimprovingglobaloutcomeskdigostaging
AT rupnowmarciaft chronickidneydiseaseinusadultswithtype2diabetesanupdatednationalestimateofprevalencebasedonkidneydiseaseimprovingglobaloutcomeskdigostaging